TY - JOUR T1 - Guillain–Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection JF - Clinical Medicine JO - Clin Med DO - 10.7861/clinmed.2020-0213 SP - clinmed.2020-0213 AU - Agustín Sancho-Saldaña AU - Álvaro Lambea-Gil AU - Jose Luis Capablo Liesa AU - Maria Rosario Barrena Caballo AU - Maria Haddad Garay AU - David Rivero Celada AU - Marta Serrano-Ponz Y1 - 2020/06/09 UR - http://www.rcpjournals.org/content/early/2020/06/08/clinmed.2020-0213.abstract N2 - Introduction Patients with coronavirus disease 2019 (COVID-19) typically present with respiratory symptoms, but little is known about the disease's potential neurological complications.We report a case of Guillain–Barré syndrome (GBS) following a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in association with leptomeningeal enhancement.Case presentation A 56-year-old woman presented with recent unsteadiness and paraesthesia in both hands. Fifteen days earlier, she complained of fever, dry cough and shortness of breath. Her chest X-ray showed a lobar consolidation and PCR was positive for SARS-CoV-2; she was admitted due to mild COVID-19 pneumonia.In the first 48 hours of hospitalisation, she started to experience lumbar pain and weakness of the proximal lower extremities, progressing to bilateral facial nerve palsy, oropharyngeal weakness and severe proximal tetraparesis with cervical flexion 2/5 on the MRC scale. A full spine magnetic resonance imaging (MRI) scan showed a brainstem and cervical leptomeningeal enhancement. Analysis of cerebrospinal fluid (CSF) revealed albumin–cytological dissociation. Microbiological studies on CSF, including SARS-CoV-2, were negative. Nerve conduction studies were consistent with demyelinating neuropathy. She was treated with intravenous immunoglobulin, with significant neurological improvement noted over the next 2 weeks.Conclusion Leptomeningeal enhancement is an atypical feature in GBS, but could be a marker of its association with SARS-CoV-2 infection. ER -